SB3510 defines terms and sets the scope for FDA inspections of biosimilar establishments. It directs a public meeting within 180 days to discuss mutual recognition agreements (MRAs) for inspections and potential expansion to remote assessments and trusted foreign partners, with a follow-on report due 180 days after the meeting.
It also requires the FDA to update inspection tools for a risk-based approach, enabling greater use of remote regulatory assessments, and to publish a strategic plan within one year addressing staffing, internal coordination, and sponsor engagement.
At a Glance
What It Does
Defines biosimilar establishment and related terms, and directs the FDA to pursue a risk-based inspection framework that includes remote regulatory assessments and expanded inspection tools.
Who It Affects
FDA inspectors and ORA staff; biosimilar establishments registered under FD&C Act section 510; sponsors of 351(k) applications; foreign regulatory partners involved in MRAs.
Why It Matters
Sets the foundation for more efficient, cross-border, and technology-enabled biosimilar oversight, with attention to staffing and inter-agency coordination.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill starts by defining key terms that determine who the FDA can inspect and under what authorities, focusing on biosimilar biological products and the facilities that manufacture them. It then moves to the process of modernizing inspections by embracing remote regulatory tools and mutual recognition with partner regulators.
The core mechanism is to hold a public meeting within six months of enactment to discuss how mutual recognition agreements could be used to inspect biosimilar establishments, and how such agreements might be expanded to include remote assessments and interactions with trusted foreign partners. A follow-up report with recommendations is due within the next six months and will be publicly released.
Finally, the bill directs the FDA to update its inspection processes to emphasize risk-based oversight and to maximize alternative tools, including remote assessments, guided by the FDA’s June 2025 guidance on remote regulatory assessments. Separately, within a year, the Secretary must publish a strategic plan addressing domestic inspection challenges—staffing, internal communication within FDA, and how to communicate inspection expectations with sponsors of 351(k) applications.
These provisions together seek to streamline oversight while preserving safety through enhanced collaboration and modern tools.
The Five Things You Need to Know
The bill defines biosimilar establishments and ties inspection scope to FDA authorities under the FD&C Act.
A public meeting on mutual recognition agreements for biosimilar inspections is required within 180 days of enactment.
A follow-up report with recommendations on MRAs for inspections must be issued within 180 days after the meeting.
The FDA must update inspection processes to enable greater use of remote regulatory assessments, aligned with the June 24, 2025 FDA guidance.
Within one year, the FDA must publish a strategic plan addressing domestic inspection staffing, internal coordination, and sponsor engagement.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions
Section 2 defines three terms for the act: a biosimilar biological product, a biosimilar biological product establishment (an establishment engaged in manufacture, preparation, propagation, or processing of a biosimilar product and registered under specified FD&C Act subsections), and the Secretary (the Secretary of Health and Human Services acting through the Commissioner of FDA). These definitions set the boundaries for which facilities fall under FDA inspection and which authorities apply.
Public meeting and report on mutual recognition agreements
Section 3(a) requires a public meeting within 180 days of enactment to discuss how mutual recognition agreements (MRAs) can be used for inspections of biosimilar establishments and to identify areas for improvement, including potential expansion into remote regulatory activities. Section 3(b) requires a report within 180 days after the meeting that includes recommendations on the use of MRAs for inspections, to be submitted to relevant committees and made publicly available.
Flexibility in inspection tools
Section 4 directs the Secretary to update inspection processes and tools to support a risk-based evaluation of biosimilar establishment inspections. This includes increasing the use of remote regulatory assessments under the FD&C Act and maximizing the use of alternative tools described in FDA guidance, with the aim of improving inspection efficiency.
FDA strategic plan on domestic inspection improvements for biosimilar facilities
Section 5 requires the Secretary to develop and publish within one year a strategic plan addressing challenges in inspecting domestic biosimilar establishments. The plan covers recruiting and retaining staff, domestic inspection challenges, improving internal communication among FDA personnel involved in inspections, and expanding external communications with sponsors about potential inspection requirements and resolving questions earlier in the process.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- FDA inspection staff gain clarity and efficiency from a risk-based framework and new tools.
- Biosimilar manufacturers gain clearer inspection expectations and potential timelines through streamlined processes.
- Sponsors of 351(k) applications benefit from earlier visibility into inspection requirements and more predictable interactions.
- Foreign regulatory partners involved in mutual recognition can participate in expanded cross-border oversight.
- Patients and healthcare systems benefit from potentially safer biosimilar products through enhanced oversight.
Who Bears the Cost
- FDA budget and staffing will need to grow to implement remote assessment capabilities and MRAs.
- Domestic biosimilar establishments may incur costs to align with updated inspection requirements and to adopt new tools and technologies.
- Foreign regulatory partners may incur additional coordination and data-sharing costs to support MRAs and remote assessments.
- Sponsors of 351(k) applications may face added documentation requirements to support remote assessments and early engagement.
- Increased reliance on technology and cross-border processes requires investment in IT systems and data-sharing infrastructure.
Key Issues
The Core Tension
The central dilemma is balancing expanded cross-border and remote inspection tools with the need for consistent, high-quality, and fully resourced domestic oversight that preserves safety and accountability.
The bill intends to create a more flexible, risk-based framework for biosimilar facility inspections and strengthen cross-border cooperation. The major implementation challenges lie in ensuring consistent standards across partners, maintaining robust safety oversight, and funding staffing and technology upgrades.
While MRAs and remote assessments promise efficiency and faster feedback, they hinge on robust data sharing, interoperability of systems, and clear, enforceable standards across jurisdictions. The plan to address domestic inspection challenges must translate into durable staffing and coordination improvements, or the intended efficiency gains may be undermined by gaps in coverage or inconsistent inspections.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.